Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma

Haematologica

Volumn 84, Issue 6, 1999, Pages 548-553

  Harousseau, Jean Luc ^a  

^a HÔTEL DIEU   (France)

Author keywords

Autologous transplantation; Multiple myeloma

Indexed keywords

CD34 ANTIGEN;

ARTICLE; AUTOTRANSPLANTATION; CELL ISOLATION; CELL SELECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL;

ANTIGENS, CD34; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033000761     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Gratwohl A, Passweg J, Baldomero H, Hermans J. Blood and marrow transplantation activity in Europe 1996. Bone Marrow Transplantation 1998; 22:227-40.
2. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335:91-7.
3. Berenson J, Wong R, Kim K, Brown N, Lichtenstein A. Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 1987; 70:1550-3.
4. Chiu EKW, Ganeshaguru K, Hoffbrand AV, Mehta AB Circulating monoclonal B lymphocytes in multiple myeloma. Br J Haematol 1989; 72:28-31.
5. Van Riet I, Heirman C, Lacor P, De Waele M, Thielemans K, Van Camp B. Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies. Br J Haematol 1989; 73:289-95.
6. Cassel A, Leibovitz N, Hornstein L, et al. Evidence for the existence of circulating monoclonal B-lymphocytes in multiple myeloma patients. Exp Hematol 1990; 18:1171-3.
7. Clofent G, Klein B, Commes T, Ghanem N, Lefranc M, Bataille R. No detectable malignant B cells in the peripheral blood of patients with multiple myeloma. Br J Haematol 1989; 71:357-61.
8. Baldini L, Cro L, Delia D, Chiorboli O, Neri A, Maiolo AT. Analysis of tumor-specific immunoglobulin gene rearrangement in peripheral blood B-cells of multiple myeloma patients. Am J Hematol 1991; 37:1-5.
9. Billadeau D, Quam L, Thomas W, et al. Detection and quantification of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80:1818-24.
10. Corradini P, Voena C, Omedé P. Detection of circulating tumor cells in multiple myeloma by a PCR-based method. Leukemia 1993; 7:1879-82.
11. Witzig TE, Gertz MA, Pineda AA, et al. Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma. Br J Haematol 1995; 89:640-2.
12. Bird JM, Bloxham D, Samson D, et al. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol 1994; 88:110-6.
13. Mariette X, Fermand JP, Brouet JL. Detection of clonal cells in peripheral blood progenitor harvests from multiple myeloma. Bone Marrow Transplant 1994; 14:47-50.
14. Dreyfus F, Ribrag V, Leblond V, et al. Detection of malignant B cells in peripheral stem cell collections after chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 1995; 15:707-11.
15. Gazitt Y, Reading CC, Hoffman R, et al. Purified CD34+ Lin- thy+ stem cells do not contain clonal myeloma cells. Blood 1995; 86:381-9.
16. Corradini P, Voena C, Astolfi M, et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85:1596-602.
17. Berenson RJ, Andrews RG, Bensinger WI, et al. Antigen CD34+ marrow cells can engraft lethally irradiated baboons. J Clin Invest 1988; 81:951-5.
18. Berenson RJ, Bensinger WJ, Hill RS, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717-22.
19. Shpall E, Jones R, Bearman S, et al. Transplantation of enriched CD34+ positive autologous bone marrow into breast cancer patients following high-dose chemotherapy: influence of CD34+ positive peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12:28-36.
20. Bensinger W, Longin K, Appelbaum F, et al. Peripheral blood stem cells collected after recombinant granulocyte colony-stimulating factor: an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87:825-31.
21. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1996; 85:588-96.
22. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collection in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86:3961-9.
23. Vescio RA, Hong CH, Cau J, et al. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 1994; 84:3283-90.
24. Szczepek AJ, Bergsagel PL, Axelsson L, Brown CB, Belch AR, Pilarski LM. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH on RNA and have patient-specific IgH VDJ gene rearrangements. Blood 1997; 89:1824-33.
25. Schiller G, Vescio R, Freytes C, et al. Transplantation of CD34+ peripheral blood progenitor cell after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86:390-7.
26. Lemoli RM, Fortuna A, Motta MR, et al. Concomitant mobilization of plasma cells and hematopoi'etic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells Blood 1996; 87:1625-34.
27. Mahé B, Milpied N, Hermouet S, et al. G-CSF alone mobilizes sufficient blood CD34+ cells for positive selection in newly diagnosed patients with myeloma and lymphoma. Br J Haematol 1996; 92:263-8.
28. Schiller G, Vescio R, Freytes C, et al. Autologous CD34+ selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplant 1998; 21:141-5.
29. Tricot G, Grazitt V, Leemhuis T, et al. Collection, tumor contamination and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 1998; 92:4489-95.
30. Gianni AM, Sienna S, Bregni M, et al. Granulocyte macrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet 1989; 2:580-5.
31. Jagannath S, Vesole DH, Glenn L, et al. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80:1666-72.
32. Martinez E, Sureda A, De Dalmases C, et al. Mobilization of peripheral blood progenitor cells by cyclophosphamide and GM-CSF in multiple myeloma. Bone Marrow Transplant 1996; 18:1-7.
33. Demuynck H, Delforge M, Verhoef G, et al. Comparative study of peripheral progenitor cell collection in patients with multiple myeloma after single dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 1995; 90:384-92.
34. Marit G, Thiessard F, Faberes F, et al. Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: monocentric study. Leukemia 1998; 12:1447-56.
35. Kotasek D, Shepherd KM, Sage RE, et al. Factors affecting blood stem cell collections following high-dose cyclosphosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplantation 1992; 9:11-7.
36. Goldschmidt H, Hegenbart U, Haas R, et al. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplantation 1996; 17:691-7.
37. Goldschmidt H, Hegenbart U, Wallmeier M, et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor. Br J Haematol 1997; 98:736-44.
38. Alegre A, Tomas JF, Martinez-Chamorro C, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplantation 1997; 20:211-21.
39. Glaspy JA, Shpall EJ, Le Maistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 8:2939.
40. Moskowitz CH, Stiff P, Gordon MS, et al. Recombinant methionyl human stem cell factor filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients. Results of a phase I/II trial. Blood 1997; 89:3136.
41. Tricot G, Jagannath S, Desikan KR, et al. Superior mobilization of peripheral blood progenitor cells (PBPC) with r-metHuSCF (SCF) and r-metHuG-CSF (filgrastim) in heavily pretreated multiple myeloma (MM) patients [abstract]. Blood 1996; 88:388a.
42. Weaver A, Ryder D, Crowther D, Dexter TM, Testa NG. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 1996; 9:3323.
43. Shpall EJ, Wheeler CA, Turner SA, et al. A randomized phase 3 study of PBPC mobilization by stem cell factor (SCF, stemgen R) and filgrastim in patients with high-risk breast cancer. Blood 1997 (abstr); 90:51a.
44. Stiff P, Gingrich R, Luger S, et al. Improved PBPC collection using Stemgen R (Stem Cell Factor) and filgrastim (G-CSF) compared to G-CSF alone in heavily pretreated lymphoma and Hodgkin's disease patients [abstract]. Blood 1997; 90 (10 Suppl. 1): 591a.
45. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89:789.